Stock VRAX VIRAX BIOLABS GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 16:26:23 06/05/2024 BST 		5-day change 1st Jan Change
0.615 USD +0.18% Intraday chart for Virax Biolabs Group Limited -2.18% -57.88%
04-25 Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 CI
01-12 Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI

Valuation

Fiscal Period: March 2023
Capitalization 1 10.81
Enterprise Value (EV) 1 1.556
P/E ratio -1.35 x
Yield -
Capitalization / Revenue 1,263 x
EV / Revenue 182 x
EV / EBITDA -
EV / FCF -573,924 x
FCF Yield -0%
Price to Book 1.18 x
Nbr of stocks (in thousands) 1,555
Reference price 2 6.954
Announcement Date 14/06/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2020 2021 2022 2023
Net sales 1 0.0999 0.1238 - 0.008561
EBITDA - - - -
EBIT 1 -0.6512 -0.6445 -1.734 -5.733
Operating Margin -652.05% -520.54% - -66,963.68%
Earnings before Tax (EBT) 1 -0.7395 -0.6729 -1.75 -5.458
Net income 1 -0.7104 -0.651 -1.709 -5.457
Net margin -711.32% -525.75% - -63,748.32%
EPS 2 -6.807 -2.707 -1.787 -5.134
Free Cash Flow - -0.2291 -0.5484 -2.711
FCF margin - -185.06% - -31,666.57%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 27/12/21 27/12/21 12/08/22 14/06/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2023 S2 2024 S1
Net sales 1 0.0028 0.0765
EBITDA - -
EBIT - -
Operating Margin - -
Earnings before Tax (EBT) - -
Net income - -
Net margin - -
EPS - -
Dividend per Share - -
Announcement Date 14/06/23 12/01/24
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023
Net Debt 1 0.73 0.16 - -
Net Cash position 1 - - 0.02 9.26
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -0.23 -0.55 -2.71
ROE (net income / shareholders' equity) - 65.7% 173% -142%
ROA (Net income/ Total Assets) - -1,295% -2,454% -72.7%
Assets 1 - 0.0503 0.0696 7.51
Book Value Per Share 2 -10.10 -0.7000 -0.9800 5.870
Cash Flow per Share 2 0.2200 0.0200 0.0200 6.020
Capex - - - -
Capex / Sales - - - -
Announcement Date 27/12/21 27/12/21 12/08/22 14/06/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VIRAX BIOLABS GROUP LIMITED Stock Virax Biolabs Group Limited
-57.88% 1.45M
MODERNA, INC. Stock Moderna, Inc.
+21.67% 47.9B
LONZA GROUP AG Stock Lonza Group AG
+46.56% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.39% 40.7B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.67% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.57% 19.27B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.42% 12.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.15% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.85% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VRAX Stock
  4. Financials Virax Biolabs Group Limited